News
$Aura Biosciences (AURA.US)$ Reuters· 1 min ago!
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-SAR in Patients With Non-Muscle-Invasive Bladder Cancer (Nmibc) in Ongoing Phase 1 Trial! No adverse events
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-SAR in Patients With Non-Muscle-Invasive Bladder Cancer (Nmibc) in Ongoing Phase 1 Trial! No adverse events
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
